Active Ingredient History
Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Carcinoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Renal Cell (Phase 1)
Desmoplastic Small Round Cell Tumor (Phase 1)
Fallopian Tube Neoplasms (Phase 1)
Hamartoma (Phase 1)
Head and Neck Neoplasms (Phase 2/Phase 3)
Melanoma (Phase 1)
Neuroblastoma (Phase 1)
Osteosarcoma (Phase 1)
Ovarian Neoplasms (Phase 1)
Prostatic Neoplasms (Phase 1)
Rhabdomyosarcoma (Phase 1)
Sarcoma, Ewing (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2/Phase 3)
Triple Negative Breast Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 1)
Wilms Tumor (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue